Network pharmacology-based evaluation of natural compounds with paclitaxel for the treatment of metastatic breast cancer.

Metastatic breast cancer is a prevalent life-threatening disease. Paclitaxel (PTX) is widely used in metastatic breast cancer therapy, but the side effects limit its chemotherapeutic application. Multidrug strategies have recently been used to maximize potency and decrease the toxicity of a particular drug by reducing its dosage. Therefore, we have evaluated the combined anti-cancerous effect of PTX with tested natural compounds (andrographolide (AND), silibinin (SIL), mimosine (MIM) and trans-anethole (TA)) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, trypan blue dye exclusion assay, proliferating cell nuclear antigen (PCNA) staining, network pharmacology, molecular docking, molecular dynamics (MD) and in vivo chick chorioallantoic membrane (CAM) angiogenesis assay. We observed a reduction in the IC50 value of PTX with tested natural compounds. Further, the network pharmacology-based analysis of compound-disease-target (C-D-T) network showed that PTX, AND, SIL, MIM and TA targeted 55, 61, 56, 31 and 18 proteins of metastatic breast cancer, respectively. Molecular docking results indicated that AND and SIL inhibited the C-D-T network's core target kinase insert domain receptor (KDR) protein more effectively than others. While MD showed that the binding of AND with KDR was stronger and more stable than others. In trypan blue dye exclusion assay and PCNA staining, AND and SIL along with PTX were found to be more effective than PTX alone. CAM assay results suggested that AND, SIL and TA increase the anti-angiogenic potential of PTX. Thus, natural compounds can be used to improve the anti-cancer potential of PTX.

Cardiotonic steroids as potential Na+/K+-ATPase inhibitors - a computational study.

Cardiotonic steroids (CTS) are steroidal drugs, processed from the seeds and dried leaves of the genus Digitalis as well as from the skin and parotid gland of amphibians. The most commonly known CTS are ouabain, digoxin, digoxigenin and bufalin. CTS can be used for safer medication of congestive heart failure and other related conditions due to promising pharmacological and medicinal properties. Ouabain isolated from plants is widely utilized in in vitro studies to specifically block the sodium potassium (Na+/K+-ATPase) pump. For checking, whether ouabain derivatives are robust inhibitors of Na+/K+-ATPase pump, molecular docking simulation was performed between ouabain and its derivatives using YASARA software. The docking energy falls within the range of 8.470 kcal/mol to 7.234 kcal/mol, in which digoxigenin was found to be the potential ligand with the best docking energy of 8.470 kcal/mol. Furthermore, pharmacophore modeling was applied to decipher the electronic features of CTS. Molecular dynamics simulation was also employed to determine the conformational properties of Na+/K+-ATPase-ouabain and Na+/K+-ATPase-digoxigenin complexes with the plausible structural integrity through conformational ensembles for 100 ns which promoted digoxigenin as the most promising CTS for treating conditions of congestive heart failure patients.

An integrated computational approach to identify GC minor groove binders using various molecular docking scoring functions, dynamics simulations and binding free energy calculations.

Understanding the DNA-ligand interaction mechanism is of utmost importance to design selective inhibitors targeting the GC- and AT-rich DNA. This forms a primary strategy to block the association of transcription factors to promoters and subsequently, reduce the expression of genes. We present here an integrated approach combining various docking scoring functions, selective ligand-based pharmacophore models, molecular dynamics simulations and binding free energy calculations to prioritize natural compounds specific to GC minor groove binding. The approach initially applies a selective ligand-based pharmacophore model built upon known GC minor groove binders to identify potential GC minor groove binders from natural compound repositories. These GC minor groove binders were then cross-examined with selective pharmacophore models (controls) based on AT-rich binders and GC intercalators to assess its unfitness. This approach involves the calculation of binding energies of known GC- and AT minor groove binders using three scoring functions without any constraint on groove specificity of GC- and AT-rich DNA. The evaluation of empirical scoring functions led to enumeration of a new parameter, the energy difference computed using Glide (sensitivity = 80%) to recognize GC-rich binders effectively. Molecular dynamics simulations and binding free energy calculations (MM/GBSA) constituted the final phase of this approach to analyze the interactions of natural molecules (hits) with GC-rich DNA comprehensively. Seven natural molecules were selected which exhibited fewer fluctuations in RMSD and RMSF profiles and better GC-rich DNA binding with low free energies of binding. These natural hits prioritized by this integrated approach can be tested in DNA binding assay.Communicated by Ramaswamy H. Sarma.